Tasks and objectives of the ADVANCE study. Design of the study. Rationale for the use of diabeton MB
https://doi.org/10.14341/2072-0351-5389
Abstract
Результаты исследования ADVANCE, безусловно, будут иметь огромное значение для реальной клинической практики, поскольку результаты подобных исследований помогают разработать эффективную систему профилактики сахарного диабета и, следовательно, уменьшить последствия грядущего резкого роста распространенности этого заболевания.
References
1. Guillasseau PJ, Greb W. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified realease once daily. Diabete Metab. 2001; 27:133-137.
2. Guillasseau PJ. Compliance and optimization of oral antidiabetic therapy. A longitudinal study, Presse Med. 2004; 33:156-160.
3. Drouin P. DIAMICRON MR study groop. DIAMICRON MR once daily is effective and well tolerated in type 2 diabetes. A doubleblind, randomized, multinational study. J. Diabetes Complications. 2000; 14:185-191.
4. O'Brien RS, Luo M, Balasz N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J. Diabetes Complications. 2000; 14:201-206.
5. Fava D, Cassone-Faldetta M, Lauretti O. E.a. Gliclazide improves antioxidant status and nitric oxide-mediated vasodilatation in tipe 2 diabetes. Diabetic Med. 2002; 19; 752-757.
6. Johnsen SP, Monster TBM, Olsen ML e.a. Risk and short term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther.; 13: 134-140.
7. Schernthaner G, Grimaldi A, Mario U, e.a.; GUIDE (Glucose control in type 2 diabetes Diamicron MR versus glimepiride) study: double-blinde comparison of once-daily gliclazide MR and glimepiride in tipe 2 diabetes patients. Eur J Clin Invest. 2004:34:535-542.
8. The ADVANCE Collaborative Group. N Engl J Med. 2008; 358:2560-2572.
Review
For citations:
Smirnova O.M. Tasks and objectives of the ADVANCE study. Design of the study. Rationale for the use of diabeton MB. Diabetes mellitus. 2009;12(2):6-9. (In Russ.) https://doi.org/10.14341/2072-0351-5389
Views:
1309
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
